NCT06919328View on ClinicalTrials.gov

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

NARecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

June 30, 2025

Conditions
Healthy Aging
Interventions
DIETARY_SUPPLEMENT

Niagen®

nicotinamide riboside

OTHER

NAD+

Nicotinamide adenine dinucleotide

OTHER

Placebo

bacteriostatic water

Trial Locations (1)

35801

RECRUITING

Nutraceuticals Research Institute, Huntsville

Sponsors
All Listed Sponsors
collaborator

ChromaDex, Inc.

INDUSTRY

lead

Nutraceuticals Research Institute

OTHER

NCT06919328 - Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+ | Biotech Hunter | Biotech Hunter